Assessment of local recurrence risk in extremity high-grade osteosarcoma through multimodality radiomics integration

Authors:
Publisher website
Google Scholar
Abstract
Background: A timely assessment of local recurrence (LoR) risk in extremity high-grade osteosarcoma is crucial for optimizing treatment strategies and improving patient outcomes. Purpose: To explore the potential of machine-learning algorithms in predicting LoR in patients with osteosarcoma. Material and Methods: Data from patients with high-grade osteosarcoma who underwent preoperative radiograph and multiparametric magnetic resonance imaging (MRI) were collected. Machine-learning models were developed and trained on this dataset to predict LoR. The study involved selecting relevant features, training the models, and evaluating their performance using the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC). DeLong's test was utilized for comparing the AUCs. Results: The performance (AUC, sensitivity, specificity, and accuracy) of four classifiers (random forest [RF], support vector machine, logistic regression, and extreme gradient boosting) using radiograph-MRI as image inputs were stable (all Hosmer-Lemeshow index >0.05) with the fair to good prognosis efficacy. The RF classifier using radiograph-MRI features as training inputs exhibited better performance (AUC = 0.806, 0.868) than that using MRI only (AUC = 0.774, 0.771) and radiograph only (AUC = 0.613 and 0.627) in the training and testing sets ( P <0.05) while the other three classifiers showed no difference between MRI-only and radiograph-MRI models. Conclusion: This study provides valuable insights into the use of machine learning for predicting LoR in osteosarcoma patients. These findings emphasize the potential of integrating radiomics data with algorithms to improve prognostic assessments.
Funding Information
  • Medical Science Project Research in Zhongshan (2024A020320)
  • Sanming Project of Medicine in Shenzen Municipality (SZSM202311022)
  • Shenzhen Science and Technology Program (JCYJ20230807113017035)
  • Shenzhen Clinical Research Center for Rare Diseases (LCYSSQ20220823091402005)

This publication has 33 references indexed in Scilit: